<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Focal nodular hyperplasia
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Focal nodular hyperplasia
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Focal nodular hyperplasia
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sanjiv Chopra, MD, MACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Bruce A Runyon, MD, FAASLD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 21, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Focal nodular hyperplasia (FNH) is a benign liver lesion that is composed of a proliferation of hyperplastic hepatocytes surrounding a central stellate scar. Typically, FNH is a solitary lesion that is more commonly seen in women.
        </p>
        <p>
         This topic will discuss the pathologic features, clinical features, diagnosis, and management of FNH. The approach to patients with other benign, solid liver lesions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3594.html" rel="external">
          "Hepatic hemangioma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">
          "Hepatocellular adenoma"
         </a>
         .)
        </p>
        <p>
         The approach to patients with cystic liver lesions is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3588.html" rel="external">
          "Diagnosis and management of cystic lesions of the liver"
         </a>
         .)
        </p>
        <p>
         The clinical features, diagnosis, and management of hepatocellular carcinoma are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">
          "Clinical features and diagnosis of hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2489.html" rel="external">
          "Overview of treatment approaches for hepatocellular carcinoma"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">
          "Surveillance for hepatocellular carcinoma in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2906627408">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H322708060">
         <span class="h2">
          Prevalence
         </span>
         <span class="headingEndMark">
          —
         </span>
         FNH is the second most commonly encountered benign liver lesion, while hepatic hemangioma is the most common. The estimated prevalence of FNH based on autopsy series is 0.3 to 3 percent; however the prevalence of FNH based on clinical series is lower at 0.03 percent [
         <a href="#rid1">
          1-3
         </a>
         ].
        </p>
        <p>
         There is increasing recognition of FNH among patients undergoing abdominal imaging for other reasons. In a large observational series including patients referred for ultrasound or contrast-enhanced computed tomography, the prevalence of FNH was 0.2 percent and 1.6 percent, respectively [
         <a href="#rid4">
          4,5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1993364252">
         <span class="h2">
          Age and sex
         </span>
         <span class="headingEndMark">
          —
         </span>
         FNH occurs in patients of any age, while most patients present between the ages of 35 and 50 years [
         <a href="#rid6">
          6
         </a>
         ]. FNH is uncommon in children and comprises approximately 2 percent of pediatric liver tumors [
         <a href="#rid7">
          7,8
         </a>
         ].
        </p>
        <p>
         FNH is seen in both males and females, although it is found predominantly in females (up to 90 percent) [
         <a href="#rid9">
          9,10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H214548871">
         <span class="h2">
          Possible risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most data suggest that female sex hormones (eg, oral contraceptive pills) do not appear to be a risk factor for the initial development or subsequent growth of FNH [
         <a href="#rid11">
          11-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         FNH is a proliferation of hepatocytes described as a hyperplastic (regenerative) reaction to an aberrant dystrophic artery [
         <a href="#rid16">
          16
         </a>
         ], to portal tract injury resulting in arterial to venous shunts [
         <a href="#rid17">
          17
         </a>
         ], or to a congenital vascular malformation [
         <a href="#rid18">
          18
         </a>
         ]. The hepatic stellate cells respond to oxidative stress caused by arterial hyperperfusion, and this results in the characteristic fibrous scar found in the center of the lesion (ie, central scar) [
         <a href="#rid19">
          19-22
         </a>
         ].
        </p>
        <p>
         FNH may occur in association with other vascular diseases including hereditary hemorrhagic telangiectasia [
         <a href="#rid23">
          23
         </a>
         ] and hepatic hemangiomas [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          PATHOLOGIC FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H644559040">
         <span class="h2">
          Typical form
         </span>
         <span class="headingEndMark">
          —
         </span>
         FNH is typically a firm, solitary lesion with a well-defined margin (but without a capsule), composed of benign hyperplastic hepatocytes surrounding a central stellate scar [
         <a href="#rid2">
          2
         </a>
         ]. Lesion size is usually &lt;5 cm, but measurement up to 19 cm has been reported [
         <a href="#rid24">
          24
         </a>
         ]. FNH is often in a subcapsular location and may be pedunculated. The characteristic finding is the presence of a central stellate scar  (
         <a class="graphic graphic_picture graphicRef54209" href="/z/d/graphic/54209.html" rel="external">
          picture 1
         </a>
         ) containing a large artery with multiple branches radiating through the fibrous septa to the periphery of the lesion.
        </p>
        <p>
         Microscopically, FNH is composed of normal-appearing hepatocytes grouped in nodules that are usually divided by fibrous septa radiating from the central scar  (
         <a class="graphic graphic_picture graphicRef66952" href="/z/d/graphic/66952.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef52949" href="/z/d/graphic/52949.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid9">
          9
         </a>
         ]. The fibrous septa are composed of varying degrees of enlarged portal tracts including feeding arteries, portal veins, and bile ductules [
         <a href="#rid20">
          20
         </a>
         ]. Kupffer cells are typically present, a feature that distinguishes FNH from hepatocellular adenoma, which usually lacks bile ducts and Kupffer cells [
         <a href="#rid1">
          1,24,26-28
         </a>
         ]. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Atypical forms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atypical forms of FNH include [
         <a href="#rid9">
          9
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FNH without a central scar – This variant lacks the characteristic central scar, and most of these lesions are &lt;3 cm [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FNH with steatosis – FNH with steatosis is a recognized variant that is typically seen in patients with underlying hepatic steatosis [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1266725601">
         <span class="h1">
          CLINICAL FEATURES
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Patterns of clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The spectrum of presentation of FNH ranges from asymptomatic individuals with incidental findings on imaging (or intraoperatively) to patients with nonspecific symptoms [
         <a href="#rid24">
          24,30,31
         </a>
         ].
        </p>
        <p>
         When symptoms are present, the most commonly reported symptom is abdominal pain [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Physical examination is often normal but infrequently may demonstrate hepatomegaly or an abdominal mass [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Laboratory findings
         </span>
         <span class="headingEndMark">
          —
         </span>
         Liver biochemical and function tests are typically normal in patients with FNH [
         <a href="#rid24">
          24,30
         </a>
         ]. Alpha-fetoprotein is normal.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Imaging
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Noncontrast ultrasound
         </span>
         <span class="headingEndMark">
          —
         </span>
         FNH has a generally isoechoic appearance on noncontrast ultrasound. Doppler studies show the central arteries having a spoke-wheel pattern [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2435232794">
         <span class="h3">
          Contrast-enhanced imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Characteristics of FNH seen on contrast-enhanced imaging (eg, magnetic resonance imaging [MRI], computed tomography [CT] scan, or contrast enhanced ultrasound [CEUS]) include [
         <a href="#rid9">
          9,33,34
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central scar is surrounded by a homogenous lesion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Lesion appearance differs from the surrounding liver.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Homogenous enhancement is seen during arterial phase, then the lesion returns to precontrast density during portal phase [
         <a href="#rid35">
          35-37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The lesion lacks a capsule, but its edges often appear lobulated.
        </p>
        <p>
        </p>
        <p>
         FNH features by specific imaging modality include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Magnetic resonance imaging – Administration of a liver-specific gadolinium-based magnetic resonance contrast agent produces rapid enhancement of FNH due to its arterial blood supply, producing a hyperintense lesion on early films  (
         <a class="graphic graphic_diagnosticimage graphicRef51338" href="/z/d/graphic/51338.html" rel="external">
          image 1
         </a>
         ). On delayed images it becomes more isointense with respect to normal liver. The central scar enhances on delayed imaging as contrast gradually diffuses into the fibrous center of the mass [
         <a href="#rid38">
          38-41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         On precontrast MRI, FNH may appear similar to the adjacent liver parenchyma, because FNH is composed of hepatocytes. An isointense lesion is noted on T1-weighted images, while an isointense to slightly hyperintense mass appears on T2-weighted images [
         <a href="#rid42">
          42
         </a>
         ]. The scar typically shows high-signal intensity on T2-weighted images due to vessels within the scar  (
         <a class="graphic graphic_diagnosticimage graphicRef64152" href="/z/d/graphic/64152.html" rel="external">
          image 2
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patient preparation and indications for intravenous administration of a gadolinium-based contrast agent are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         CT scan – On multiphasic CT scan, FNH may appear hypo- or isodense on precontrast images. The arterial phase shows a homogenous hyperdense lesion that generally becomes isodense during the portal venous phase [
         <a href="#rid43">
          43
         </a>
         ]. On delayed imaging, the central scar often becomes hyperdense as contrast diffuses into the fibrous scar.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contrast-enhanced ultrasonography – On CEUS, FNH typically demonstrates arterial and (early) portal venous phase enhancement, while the central arteries display a spoke-wheel pattern in the arterial phase [
         <a href="#rid36">
          36,37,44,45
         </a>
         ]. Use of CEUS in the United States has been limited, but it is more widely available in other countries. (See
         <a class="medical medical_review" href="/z/d/html/96352.html" rel="external">
          "Contrast-enhanced ultrasound for the evaluation of liver lesions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H438576032">
         <span class="h1">
          DIAGNOSTIC APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of FNH may be suspected in a patient without cirrhosis who is found to have a solid liver lesion on imaging. For patients with suspected FNH based on ultrasound or computed tomography (CT) findings, the diagnosis is made with cross-sectional, contrast-enhanced multiphase magnetic resonance imaging [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="local">
          'Contrast-enhanced imaging'
         </a>
         above.)
        </p>
        <p>
         The general approach to incidental liver lesions identified by ultrasound or CT is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/3575.html" rel="external">
          "Approach to the adult patient with an incidental solid liver lesion"
         </a>
         .)
        </p>
        <p>
         A biopsy of the lesion is not routinely indicated to confirm the diagnosis, but may be necessary if the contrast-enhanced imaging features are not typical of FNH. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.) Alternatively, patients who are symptomatic may undergo surgical resection, and the diagnosis is then confirmed with histology. (See
         <a class="local">
          'Symptomatic lesions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2870950271">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         If cross–sectional imaging of the liver lesion is not specific, additional evaluation for an alternative diagnosis may be required. The differential diagnosis includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatocellular adenoma
         </strong>
         – Although contrast-enhanced multiphasic imaging (ie, magnetic resonance imaging [MRI]) often differentiates between FNH and hepatocellular adenoma (HCA), further evaluation (eg, biopsy) may be required for definitive diagnosis. In a systematic review of six studies including over 300 patients who had multiphase MRI with hepatobiliary contrast, the sensitivity and specificity to differentiate FNH from HCA were high, with ranges from 91 to 100 percent and from 87 to 100 percent, respectively [
         <a href="#rid47">
          47
         </a>
         ]. In addition, HCA may present with acute bleeding, while bleeding is not typically seen with FNH. (See
         <a class="medical medical_review" href="/z/d/html/3590.html" rel="external">
          "Hepatocellular adenoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hepatocellular carcinoma (HCC)
         </strong>
         – In contrast to patients with FNH, patients with HCC often have history of cirrhosis. The risk factors for and diagnosis of HCC are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3597.html" rel="external">
          "Clinical features and diagnosis of hepatocellular carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3583.html" rel="external">
          "Surveillance for hepatocellular carcinoma in adults", section on 'High-risk groups'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fibrolamellar carcinoma
         </strong>
         – While more characteristic of FNH, a central scar may be present in the fibrolamellar variant of HCC. (See
         <a class="medical medical_review" href="/z/d/html/16571.html" rel="external">
          "Epidemiology, clinical manifestations, diagnosis, and treatment of fibrolamellar carcinoma", section on 'Imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H4217679123">
         <span class="h2">
          General measures for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         We generally do not insist that oral contraceptives and other estrogen-containing preparations should be discontinued. However, it is reasonable to obtain a follow-up imaging study in 6 to 12 months in women with FNH who continue taking these drugs. (See
         <a class="local">
          'Possible risk factors'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H186639318">
         <span class="h2">
          Asymptomatic lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         We do not routinely obtain surveillance imaging for asymptomatic patients with FNH because of the low risk of lesion growth or complications. In a study including 30 patients with FNH (34 lesions) who were monitored with ultrasound, 33 lesions (97 percent) either remained stable or regressed in size during a mean follow-up of 42 months [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="local">
          'Prognosis'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H4232478646">
         <span class="h2">
          Symptomatic lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptoms such as abdominal pain are uncommon, but some patients with persistent pain attributed to FNH may require procedural intervention. Surgical resection may be performed, although less invasive approaches (eg, transarterial embolization, radiofrequency ablation) have also been used [
         <a href="#rid49">
          49-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3831004301">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The prognosis for patients with FNH is generally excellent because the lesion is most often stable or may regress over time [
         <a href="#rid55">
          55,56
         </a>
         ], while complications (eg, bleeding) are very rarely reported [
         <a href="#rid57">
          57,58
         </a>
         ]. Malignant transformation has not been reported.
        </p>
        <p class="headingAnchor" id="H688644087">
         <span class="h1">
          PREGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy is not contraindicated for asymptomatic female patients with FNH who wish to conceive, in addition, we do not routinely perform surveillance liver ultrasound during pregnancy [
         <a href="#rid2">
          2,9,14,59
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3418193714">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122574.html" rel="external">
          "Society guideline links: Focal liver lesions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H94740675">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FNH is a benign liver lesion that is composed of hepatocytes surrounding a central stellate scar. Typically, FNH is a solitary lesion that is more commonly seen in women. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         FNH is a proliferation of hyperplastic hepatocytes that occurs in response to an aberrant dystrophic artery, to portal tract injury resulting in arterial to venous shunts, or to a congenital vascular malformation. The hepatic stellate cells respond to oxidative stress caused by arterial hyperperfusion, and this results in the characteristic fibrous scar found in the center of the lesion (ie, central scar. (See
         <a class="local">
          'Pathogenesis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The spectrum of presentation of FNH ranges from asymptomatic individuals with incidental findings on imaging to patients with nonspecific symptoms. When symptoms are present, the most commonly reported symptom is abdominal pain. (See
         <a class="local">
          'Patterns of clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of FNH may be suspected in a patient without cirrhosis who is found to have a solid liver lesion on imaging. For patients with suspected FNH based on ultrasound or CT findings, the diagnosis is made with cross-sectional, contrast-enhanced, multiphase magnetic resonance imaging. (See
         <a class="local">
          'Diagnostic approach'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not routinely obtain surveillance imaging to monitor asymptomatic patients with FNH because of the very low risk of lesion growth or complications. (See
         <a class="local">
          'Asymptomatic lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms such as abdominal pain are uncommon, but some patients with persistent abdominal pain may require procedural intervention. Surgical resection may be performed, although less invasive approaches (eg, transarterial embolization, radiofrequency ablation) have also been used. (See
         <a class="local">
          'Symptomatic lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The prognosis for patients with FNH is generally excellent because the lesion is most often stable or may regress over time, while complications (eg, bleeding) are very rarely reported. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Craig J, Peters R, Edmundson H. Tumors of the Liver and Intrahepatic Bile Ducts, Fasc 26, 2nd ed, DC Armed Forces Institute of Pathology, Washington, DC 1989. p.6.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marrero JA, Ahn J, Rajender Reddy K, Americal College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol 2014; 109:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karhunen PJ. Benign hepatic tumours and tumour like conditions in men. J Clin Pathol 1986; 39:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaltenbach TE, Engler P, Kratzer W, et al. Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients. Abdom Radiol (NY) 2016; 41:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horta G, López M, Dotte A, et al. [Benign focal liver lesions detected by computed tomography: Review of 1,184 examinations]. Rev Med Chil 2015; 143:197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995; 19:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reymond D, Plaschkes J, Lüthy AR, et al. Focal nodular hyperplasia of the liver in children: review of follow-up and outcome. J Pediatr Surg 1995; 30:1590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Islam N, Halder A, Ghosh R, et al. Focal nodular hyperplasia of the liver in children: A report of 2 cases. Indian J Pathol Microbiol 2019; 62:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol 2016; 65:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Corallo C, Bell J, Laverty A, et al. Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre. Abdom Radiol (NY) 2023; 48:2292.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rifai K, Mix H, Krusche S, et al. No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy. Scand J Gastroenterol 2013; 48:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'halluin V, Vilgrain V, Pelletier G, et al. [Natural history of focal nodular hyperplasia. A retrospective study of 44 cases]. Gastroenterol Clin Biol 2001; 25:1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramírez-Fuentes C, Martí-Bonmatí L, Torregrosa A, et al. Variations in the size of focal nodular hyperplasia on magnetic resonance imaging. Radiologia 2013; 55:499.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathieu D, Kobeiter H, Maison P, et al. Oral contraceptive use and focal nodular hyperplasia of the liver. Gastroenterology 2000; 118:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scalori A, Tavani A, Gallus S, et al. Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study. Am J Obstet Gynecol 2002; 186:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bioulac-Sage P, Cubel G, Balabaud C, Zucman-Rossi J. Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers. Semin Liver Dis 2011; 31:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato Y, Harada K, Ikeda H, et al. Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation. Hum Pathol 2009; 40:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mindikoglu AL, Regev A, Levi JU, et al. Focal nodular hyperplasia in identical twins. Am J Gastroenterol 2005; 100:1616.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukukura Y, Nakashima O, Kusaba A, et al. Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver. J Hepatol 1998; 29:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kondo F, Nagao T, Sato T, et al. Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension. Pathol Res Pract 1998; 194:487.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rebouissou S, Bioulac-Sage P, Zucman-Rossi J. Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008; 48:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winterer JT, Kotter E, Ghanem N, Langer M. Detection and characterization of benign focal liver lesions with multislice CT. Eur Radiol 2006; 16:2427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wanless IR, Gryfe A. Nodular transformation of the liver in hereditary hemorrhagic telangiectasia. Arch Pathol Lab Med 1986; 110:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen BN, Fléjou JF, Terris B, et al. Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999; 23:1441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathieu D, Zafrani ES, Anglade MC, Dhumeaux D. Association of focal nodular hyperplasia and hepatic hemangioma. Gastroenterology 1989; 97:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishak KG, Rabin L. Benign tumors of the liver. Med Clin North Am 1975; 59:995.
          </a>
         </li>
         <li class="breakAll">
          Goodman ZD. Benign Tumors of the Liver. In: Neoplasms of the Liver, Okuda K, Ishak KD (Eds), Springer, Tokyo 1987. p.105.
         </li>
         <li class="breakAll">
          Klatskin G, Conn H. Neoplasms of the Liver and Intrahepatic Bile Ducts. In: Histopathology of the Liver, Oxford University Press, New York 1993. p.367.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ronot M, Paradis V, Duran R, et al. MR findings of steatotic focal nodular hyperplasia and comparison with other fatty tumours. Eur Radiol 2013; 23:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherqui D, Rahmouni A, Charlotte F, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995; 22:1674.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luciani A, Kobeiter H, Maison P, et al. Focal nodular hyperplasia of the liver in men: is presentation the same in men and women? Gut 2002; 50:877.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartolotta TV, Taibbi A, Matranga D, et al. Hepatic focal nodular hyperplasia: contrast-enhanced ultrasound findings with emphasis on lesion size, depth and liver echogenicity. Eur Radiol 2010; 20:2248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buetow PC, Pantongrag-Brown L, Buck JL, et al. Focal nodular hyperplasia of the liver: radiologic-pathologic correlation. Radiographics 1996; 16:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vilgrain V, Fléjou JF, Arrivé L, et al. Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients. Radiology 1992; 184:699.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brancatelli G, Federle MP, Grazioli L, et al. Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients. Radiology 2001; 219:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim MJ, Lim HK, Kim SH, et al. Evaluation of hepatic focal nodular hyperplasia with contrast-enhanced gray scale harmonic sonography: initial experience. J Ultrasound Med 2004; 23:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietrich CF, Schuessler G, Trojan J, et al. Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound. Br J Radiol 2005; 78:704.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irie H, Honda H, Kaneko K, et al. MR imaging of focal nodular hyperplasia of the liver: value of contrast-enhanced dynamic study. Radiat Med 1997; 15:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahfouz AE, Hamm B, Taupitz M, Wolf KJ. Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging. Radiology 1993; 186:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rummeny E, Weissleder R, Sironi S, et al. Central scars in primary liver tumors: MR features, specificity, and pathologic correlation. Radiology 1989; 171:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mathieu D, Rahmouni A, Anglade MC, et al. Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging. Radiology 1991; 180:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mattison GR, Glazer GM, Quint LE, et al. MR imaging of hepatic focal nodular hyperplasia: characterization and distinction from primary malignant hepatic tumors. AJR Am J Roentgenol 1987; 148:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson SK, Johnson CD, Bender CE, Welch TJ. CT of focal nodular hyperplasia of the liver. AJR Am J Roentgenol 2000; 174:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quaia E. The real capabilities of contrast-enhanced ultrasound in the characterization of solid focal liver lesions. Eur Radiol 2011; 21:457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giambelluca D, Taibbi A, Midiri M, Bartolotta TV. The "spoke wheel" sign in hepatic focal nodular hyperplasia. Abdom Radiol (NY) 2019; 44:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McInnes MD, Hibbert RM, Inácio JR, Schieda N. Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review. Radiology 2015; 277:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuo YH, Wang JH, Lu SN, et al. Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography. J Clin Ultrasound 2009; 37:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amesur N, Hammond JS, Zajko AB, et al. Management of unresectable symptomatic focal nodular hyperplasia with arterial embolization. J Vasc Interv Radiol 2009; 20:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedayati P, VanSonnenberg E, Shamos R, et al. Treatment of symptomatic focal nodular hyperplasia with percutaneous radiofrequency ablation. J Vasc Interv Radiol 2010; 21:582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Charny CK, Jarnagin WR, Schwartz LH, et al. Management of 155 patients with benign liver tumours. Br J Surg 2001; 88:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perrakis A, Vassos N, Grützmann R, Croner RS. What is Changing in Indications and Treatment of Focal Nodular Hyperplasia of the Liver. Is There Any Place for Surgery? Ann Hepatol 2017; 16:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sato H, Monden K, Iwasaki T, et al. Large focal nodular hyperplasia of the liver treated with transcatheter arterial embolization and laparoscopic resection: A case report. Asian J Endosc Surg 2023; 16:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan JY, Duan F, Fu JX, et al. Outcomes of transarterial embolization for large symptomatic focal nodular hyperplasia in 17 pediatric patients. Dig Liver Dis 2023; 55:899.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Di Stasi M, Caturelli E, De Sio I, et al. Natural history of focal nodular hyperplasia of the liver: an ultrasound study. J Clin Ultrasound 1996; 24:345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leconte I, Van Beers BE, Lacrosse M, et al. Focal nodular hyperplasia: natural course observed with CT and MRI. J Comput Assist Tomogr 2000; 24:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demarco MP, Shen P, Bradley RF, Levine EA. Intraperitoneal hemorrhage in a patient with hepatic focal nodular hyperplasia. Am Surg 2006; 72:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rahili A, Cai J, Trastour C, et al. Spontaneous rupture and hemorrhage of hepatic focal nodular hyperplasia in lobus caudatus. J Hepatobiliary Pancreat Surg 2005; 12:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weimann A, Mössinger M, Fronhoff K, et al. Pregnancy in women with observed focal nodular hyperplasia of the liver. Lancet 1998; 351:1251.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3577 Version 22.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Craig J, Peters R, Edmundson H. Tumors of the Liver and Intrahepatic Bile Ducts, Fasc 26, 2nd ed, DC Armed Forces Institute of Pathology, Washington, DC 1989. p.6.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25135008" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : ACG clinical guideline: the diagnosis and management of focal liver lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3950039" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Benign hepatic tumours and tumour like conditions in men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26830608" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prevalence of benign focal liver lesions: ultrasound investigation of 45,319 hospital patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25860362" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : [Benign focal liver lesions detected by computed tomography: Review of 1,184 examinations].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7740799" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8583330" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Focal nodular hyperplasia of the liver in children: review of follow-up and outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30971551" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Focal nodular hyperplasia of the liver in children: A report of 2 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27085809" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : EASL Clinical Practice Guidelines on the management of benign liver tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37043025" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Suspected focal nodular hyperplasia in male adults: 10-year experience from a large liver centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23110461" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : No evidence of substantial growth progression or complications of large focal nodular hyperplasia during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11845055" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : [Natural history of focal nodular hyperplasia. A retrospective study of 44 cases].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22742826" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Variations in the size of focal nodular hyperplasia on magnetic resonance imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10702207" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Oral contraceptive use and focal nodular hyperplasia of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854634" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Oral contraceptives and the risk of focal nodular hyperplasia of the liver: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21344354" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Revisiting the pathology of resected benign hepatocellular nodules using new immunohistochemical markers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18799187" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Hepatic stellate cells are activated around central scars of focal nodular hyperplasia of the liver--a potential mechanism of central scar formation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15984990" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Focal nodular hyperplasia in identical twins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9764996" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Angioarchitecture and blood circulation in focal nodular hyperplasia of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9728365" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Etiological analysis of focal nodular hyperplasia of the liver, with emphasis on similar abnormal vasculatures to nodular regenerative hyperplasia and idiopathic portal hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17997499" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16724204" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Detection and characterization of benign focal liver lesions with multislice CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3754122" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nodular transformation of the liver in hereditary hemorrhagic telangiectasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10584697" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2542117" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Association of focal nodular hyperplasia and hepatic hemangioma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/167242" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Benign tumors of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/167242" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Benign tumors of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/167242" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Benign tumors of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23064717" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : MR findings of steatotic focal nodular hyperplasia and comparison with other fatty tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7489973" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12010893" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Focal nodular hyperplasia of the liver in men: is presentation the same in men and women?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20407902" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hepatic focal nodular hyperplasia: contrast-enhanced ultrasound findings with emphasis on lesion size, depth and liver echogenicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8966294" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Focal nodular hyperplasia of the liver: radiologic-pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1509052" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Focal nodular hyperplasia of the liver: MR imaging and pathologic correlation in 37 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11274535" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Focal nodular hyperplasia: CT findings with emphasis on multiphasic helical CT in 78 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992369" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Evaluation of hepatic focal nodular hyperplasia with contrast-enhanced gray scale harmonic sonography: initial experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16046421" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Differentiation of focal nodular hyperplasia and hepatocellular adenoma by contrast-enhanced ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9134582" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : MR imaging of focal nodular hyperplasia of the liver: value of contrast-enhanced dynamic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8416554" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Hypervascular liver lesions: differentiation of focal nodular hyperplasia from malignant tumors with dynamic gadolinium-enhanced MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2539605" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Central scars in primary liver tumors: MR features, specificity, and pathologic correlation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2052704" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Focal nodular hyperplasia of the liver: assessment with contrast-enhanced TurboFLASH MR imaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3030082" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : MR imaging of hepatic focal nodular hyperplasia: characterization and distinction from primary malignant hepatic tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10701613" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : CT of focal nodular hyperplasia of the liver.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21107578" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The real capabilities of contrast-enhanced ultrasound in the characterization of solid focal liver lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30488100" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : The "spoke wheel" sign in hepatic focal nodular hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15955857" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26020440" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Focal Nodular Hyperplasia and Hepatocellular Adenoma: Accuracy of Gadoxetic Acid-enhanced MR Imaging--A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18855931" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Natural course of hepatic focal nodular hyperplasia: a long-term follow-up study with sonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19328431" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Management of unresectable symptomatic focal nodular hyperplasia with arterial embolization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20138547" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of symptomatic focal nodular hyperplasia with percutaneous radiofrequency ablation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11412249" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Management of 155 patients with benign liver tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28425402" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : What is Changing in Indications and Treatment of Focal Nodular Hyperplasia of the Liver. Is There Any Place for Surgery?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37037454" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Large focal nodular hyperplasia of the liver treated with transcatheter arterial embolization and laparoscopic resection: A case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36669995" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Outcomes of transarterial embolization for large symptomatic focal nodular hyperplasia in 17 pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8873856" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Natural history of focal nodular hyperplasia of the liver: an ultrasound study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10667661" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Focal nodular hyperplasia: natural course observed with CT and MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16808214" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Intraperitoneal hemorrhage in a patient with hepatic focal nodular hyperplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15868078" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Spontaneous rupture and hemorrhage of hepatic focal nodular hyperplasia in lobus caudatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9643751" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Pregnancy in women with observed focal nodular hyperplasia of the liver.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
